Fulcrum Therapeutics, Inc. (FULC) stock
FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.75+0.04 (+1.08%)
Close on Nov 17, 2026Market cap $286.12MP/E –Yield –
Fulcrum Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Fulcrum Therapeutics's price to sales ratio was 2.6× on Apr 30, 2025, against 157.4× a year earlier. Over the last 4 years it ranged from 1.9× to 229.8×, with a median of 32.1×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2025 | Apr 30, 2025 | 2.6× | −0.5 |
| 2024 | Dec 31, 2024 | 3.1× | −131.1 |
| 2023 | Dec 29, 2023 | 134.3× | +112.0 |
| 2022 | Dec 30, 2022 | 22.3× | −16.8 |
| 2021 | Dec 31, 2021 | 39.1× | – |
See a number that looks wrong?